Level of A1C control and its predictors among Lebanese type 2 diabetic patients

dc.contributor.authorNoureddine, Hanan
dc.contributor.authorNakhoul, Nancy F.
dc.contributor.authorGalal, Amal
dc.contributor.authorSoubra, Lama
dc.contributor.authorSaleh, Mounzer
dc.contributor.departmentEmergency Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:41:26Z
dc.date.available2025-01-24T11:41:26Z
dc.date.issued2014
dc.description.abstractAim: Lebanon is among the top 10 countries with the highest prevalence of diabetes in the Middle East region with estimates reaching as high as 16.6% in adults aged 20-79 years. The objective of this study was to assess the level of A1C control among a cohort of type 2 diabetic patients and factors associated with uncontrolled A1C. Methods: We carried out a retrospective observational study among type 2 diabetes mellitus patients attending an outpatient endocrinologist's clinic between June 2008 and July 2012 in Beirut, Lebanon. Two groups were compared, based on their diabetic control (A1C < 7% and A1C ≥ 7%). Results: A total of 551 patients were included in this study, where 31.8% attained A1C control. Crude analyses showed that some factors were significantly associated with uncontrolled A1C, and these were long-standing diabetes, diabetes-related complications, uncontrolled blood pressure, lipid profile, as well as the use of metformin, sulfonylurea, or insulin. When multivariate analysis was carried out, the chances of having uncontrolled A1C were significantly higher among patients who developed neuropathy (odds ratio [OR] 2.08, 95% confidence interval [CI] 1.11-3.90), had uncontrolled triglycerides (OR 1.98, 95% CI 1.33-2.94), used insulin (OR 4.52, 95% CI 2.32-8.83), and sulfonylureas (OR 2.88, 95% CI 1.88-4.40). Uncontrolled diabetes is more likely to exist in patients with neuropathy, uncontrolled triglycerides and those using insulin or sulfonylurea. Further research is needed to confirm the findings. © 2014, SAGE Publications. All rights reserved.
dc.identifier.doihttps://doi.org/10.1177/2042018814544890
dc.identifier.eid2-s2.0-84905979105
dc.identifier.urihttp://hdl.handle.net/10938/29732
dc.language.isoen
dc.relation.ispartofTherapeutic Advances in Endocrinology and Metabolism
dc.sourceScopus
dc.subjectA1c control
dc.subjectDiabetes mellitus type 2
dc.subjectLebanon
dc.subjectPredictors
dc.subject2, 4 thiazolidinedione derivative
dc.subjectCholesterol
dc.subjectHemoglobin a1c
dc.subjectHigh density lipoprotein
dc.subjectIncretin
dc.subjectInsulin
dc.subjectLow density lipoprotein
dc.subjectMetformin
dc.subjectSulfonylurea
dc.subjectTriacylglycerol
dc.subjectUnclassified drug
dc.subjectAdult
dc.subjectAged
dc.subjectAlbuminuria
dc.subjectArticle
dc.subjectBlood pressure
dc.subjectDiabetes control
dc.subjectDrug use
dc.subjectFemale
dc.subjectHuman
dc.subjectLipid analysis
dc.subjectMajor clinical study
dc.subjectMale
dc.subjectNeuropathy
dc.subjectNon insulin dependent diabetes mellitus
dc.subjectObservational study
dc.subjectPriority journal
dc.subjectRetinopathy
dc.subjectRetrospective study
dc.titleLevel of A1C control and its predictors among Lebanese type 2 diabetic patients
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2014-10702.pdf
Size:
769.64 KB
Format:
Adobe Portable Document Format